Report by Mail Download PDF

Annual Report 2017
Downloads

Halbjahresbericht_2018_en.pdf

Half-Year Report 2018

8 pages
Zeitung_GB2017_Vollversion_final_en.pdf

Annual Report

Full Version, 76 pages
Zeitung_Lagebericht_Strategie_GB2017_final_en.pdf

Progress Report and "Evolve" Strategy

2x12 pages
Zeitung_Corporate_Governance_GB2017_final_en.pdf

Corporate Governance

8 pages
Zeitung_Vergu__tung_GB2017_final_en.pdf

Remuneration Report

8 pages
Zeitung_Nachhaltigkeit_GB2017_final_en.pdf

Sustainability Report

12 pages
Finanzbericht_Online-PDF_2017_en.pdf

Financial Report

62 pages

Annual Report 2017
Report by Mail

per Post bestellen

per Post bestellen

Globally Positioned
Focused
Profitable

Progress Report

“We will do everything in our power to ensure that the company remains on its successful course.”

Dear Shareholders

For the 2017 financial year, the Siegfried Group again reported a very sound result. Sales amounted to 750.5 million Swiss francs, corresponding to a growth of 4.6%. Following years of significant acquisitions, Siegfried achieved robust organic growth. Earnings before interest, taxes and amortization (EBITDA) grew significantly by 17.8% to 114.0 million francs, corresponding to an EBITDA margin of 15.2%. The margin is within the targeted range of 15 – 20%. Siegfried achieved net profit of 39.7 million francs, which is clearly above that reported the previous year (27.9 million francs), representing a growth of 42.4%.

Dr. Andreas Casutt
Chairman of the Board of Directors

Dr. Rudolf Hanko
Chief Executive Officer

The Year 2017 in Review

Commentaries & Interviews

Interview on the “Evolve” Strategy 

Dr. Rudolf Hanko,
Chief Executive Officer

Link to PDF

Growth and Widening of Margins

Dr. Reto Suter,
Chief FInancial Officer

Link to PDF

Locations

Siegfried, a worldwide leading CDMO, produces active pharmaceutical ingredients (APIs), intermediates and finished products from a single source. Our core competence is process development and the integration of complementary chemical and pharmaceutical capabilities in a single business model. 

Locations

1 Zofingen 

2 Pennsville

3 Hal Far 

4 Irvine

5 Nantong

6 Hameln 

7 Minden

8 St. Vulbas

9 Evionnaz

Information for Investors

Publications

Halbjahresbericht_2018_en.pdf

Half-Year Report 2018

8 pages
Zeitung_GB2017_Vollversion_final_en.pdf

Annual Report

Full Version, 76 pages
Zeitung_Lagebericht_Strategie_GB2017_final_en.pdf

Progress Report and "Evolve" Strategy

2x12 pages
Zeitung_Corporate_Governance_GB2017_final_en.pdf

Corporate Governance

8 pages
Zeitung_Vergu__tung_GB2017_final_en.pdf

Remuneration Report

8 pages
Zeitung_Nachhaltigkeit_GB2017_final_en.pdf

Sustainability Report

12 pages
Finanzbericht_Online-PDF_2017_en.pdf

Financial Report

62 pages

Media Releases

August 21, 2018 — 6.05  a.m.

Siegfried Reports Higher Sales and Further Improved Margin for First Half Year

  • The Siegfried Group (SIX: SFZN) reports net sales for the first half of 2018 of 377.2 million francs (2017: 349.1 million francs), corresponding to a growth rate of 8.0% (5.2% in local currencies).
  • Earnings before interest, taxes, depreciation and amortization (EBITDA) and before special effects grew by 20.1% to 63.5 million francs (2017: 52.9 million francs). EBITDA after special effects was stated as 62.0 million francs.
  • The EBITDA margin rose by 1.6 percentage points to 16.8% (2017: 15.2%).
  • Net profit before special effects increased by 41.1% to 30.5 million francs (2017: 21.6 million francs).
  • Cash flow from operating activity rose by 89.5% to 35.6 million francs (2017: 18.8 million francs).

Contact

We would be pleased to hear from you.

Peter Gehler
Chief Communications Officer
peter.gehler@siegfried.ch
+41 62 746 1148

Dr. Reto Suter
Chief Financial Officer
reto.suter@siegfried.ch
+41 62 746 1135